Managed Healthcare Executive February 29, 2024
Briana Contreras

AMCP CEO Susan Cantrell spoke with Managed Healthcare Executive about the challenges of pinpointing specific causes for high drug prices.

Cantrell emphasized the crucial role of innovation in driving prescription drug costs, sharing the exciting advancements in therapies for long-standing health issues. However, she did caution against some policy solutions that might intervene in any innovations.

Additionally, she stressed the importance of payment models, supporting the Medicaid Value-Based Payments for Patients (MVP) Act to enhance Medicaid patients’ access to high-cost therapies.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending, Trends
Closing the women’s health gap: Biopharma’s untapped opportunity
The next 15 drugs for Medicare price negotiations
Medicare Negotiations Could Fuel, Not Stifle, Innovation
Four Opportunities To Revitalize The US Biomedical Research Enterprise
FDA approves 1st monotherapy drug for treatment-resistant depression

Share This Article